Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Drug Name | TJ011133 |
Trade Name | |
Synonyms | TJC4|TJ 011133|TJ-011133|Lemzoparlimab |
Drug Descriptions |
TJ011133 (TJC4) is a monocloncal antibody to CD74, which blocks the interaction of CD74 with SIRPA to enhance macrophage mediated phagocytosis of tumor cells (Blood (2019) 134 (Supplement_1): 4063). |
DrugClasses | CD74 Antibody 3 |
CAS Registry Number | NA |
NCIT ID | C163977 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Azacitidine + TJ011133 | Azacitidine TJ011133 | 0 | 1 |
Azacitidine + TJ011133 + Venetoclax | Azacitidine TJ011133 Venetoclax | 0 | 1 |
Carfilzomib + Dexamethasone + TJ011133 | Carfilzomib Dexamethasone TJ011133 | 0 | 1 |
Daratumumab + Dexamethasone + TJ011133 | Daratumumab Dexamethasone TJ011133 | 0 | 1 |
Dexamethasone + Pomalidomide + TJ011133 | Dexamethasone Pomalidomide TJ011133 | 0 | 1 |
Dexamethasone + TJ011133 | Dexamethasone TJ011133 | 0 | 1 |
Pembrolizumab + TJ011133 | Pembrolizumab TJ011133 | 0 | 1 |
Rituximab + TJ011133 | Rituximab TJ011133 | 0 | 1 |
TJ011133 | TJ011133 | 0 | 2 |